Last €140.05 EUR
Change Today +0.051 / 0.04%
Volume 51.0
As of 1:03 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

8510 Colonnade Center Drive

Raleigh, NC 27615

United States

Phone: 919-862-1000

Fax: 919-862-1095

Salix Pharmaceuticals, Ltd., a specialty pharmaceutical company, is engaged in acquiring, developing, and commercializing prescription drugs and medical devices used in the treatment of various gastrointestinal disorders, which are those affecting the digestive tract. The company sells its products to pharmaceutical wholesalers. These direct customers resell and distribute its products to and through pharmacies to patients who have had its products prescribed by doctors. The company markets its products, and intends to market future products, if approved by the Food and Drug Administration (FDA), to the U.S. gastroenterologists, hepatologists, endocrinologists, colorectal surgeons, primary care, and other physicians through its own direct sales force. Products Salix Products Xifaxan (rifaximin) Tablets Xifaxan, the company’s primary product, is a gastrointestinal-specific oral antibiotic. Xifaxan 550 mg is approved by the FDA for reduction in risk of overt HE recurrence in patients 18 years of age or older. Additionally, the FDA approved Xifaxan 200 mg in May 2004 for the treatment of patients 12 years of age and older with TD caused by noninvasive strains of E coli. Xifaxan 550 mg has orphan drug exclusivity, granted by the FDA, for HE through March 24, 2017. The company has 15 patents potentially providing combined protection on the Xifaxan molecule until 2027 and method of use patent protection for the TD, HE and IBS indications until 2029. The company filed in Canada in January 2013 to market Xifxan550 to treat hepatic encephalopathy and received marketing approval in August 2013. Apriso (mesalamine) Extended-Release Capsules Apriso is a locally-acting aminosalicylate that is approved by the FDA. It is the only delayed and extended release mesalamine product that is FDA-approved for the maintenance of remission of UC in adults. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product’s prolonged release mechanism might allow the company to expand the range of treatment options for UC. MoviPrep (PEG 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid) Oral Solution MoviPrep is a patent-protected, liquid PEG bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations. The company has a sublicense agreement that granted Novel, a license under the patents covering MoviPrep permitting Novel to launch a generic version of MoviPrep no later than September 24, 2018. Relistor (methylnaltrexone bromide) Relistor SI is indicated for the treatment of OIC in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved by the FDA and it is approved for use in approximately 55 countries worldwide. The company’s pre-filled syringe Relistor product has patent protection until December 2030. There are also pending applications on its Relistor products that if issued would provide further protection until 2024 and 2031. OsmoPrep (Sodium Phosphate Monobasic Monohydrate, USP, Sodium Phosphate Dibasic Anhydrous, USP) Tablets OsmoPrep tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. OsmoPrep, approved by the FDA, is the only tablet bowel cleansing product marketed in the United States. The company has a sublicense agreement that granted Novel a license under the patents covering OsmoPrep permitting Novel to launch a generic version of OsmoPrep no later than November 16, 2019. Solesta Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XP2:GR €140.05 EUR +0.051

XP2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $53.81 USD +0.34
Alkermes PLC $70.25 USD -0.98
Jazz Pharmaceuticals PLC $170.09 USD -5.10
Lupin Ltd 1,747 INR +9.45
Recordati SpA €16.09 EUR -0.17
View Industry Companies

Industry Analysis


Industry Average

Valuation XP2 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.3x
Price/Book 19.0x
Price/Cash Flow 101.0x
TEV/Sales 4.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at